Contents13 - Over 90% of vaccines in UK imported from FlandersAstrid Geeraerts explores the significance of Flanders in the vaccine industry, and how this has been impacted by the COVID-19 pandemic and Brexit16 -The future of follicular lymphoma treatmentDr Mitchell Smith and Dr Julie Dodds discuss the new and exciting research being conducted into FL, as well as the Follicular Lymphoma Foundation’s new research grantsTop NewsPage 4 -Stem cell transplants could be offered to MS patients in new trialPage 6 – European Commission gives orphan status to selinexor to treat myelofribrosisPage 7 – AstraZeneca and MSD launch prostate cancer awareness campaignPage 10 – Siemens Healthineers and Atrium Health team up in $140m dealPage 12 - Eli Lilly loses billions on stock valuation after fake account verified by TwitterOur TeamExecutive Director – PMGroup Worldwide Ltd
Karl Equi
Group Managing Editor
Iona Everson
ieverson@pmlive.comEditorial and Content Assistant
Lina Adams
lina@pharmafile.comSales Manager
Eliot Haynes
eliot@pharmafile.comDesign & Layout
Peter May
designer@samedanltd.com
Pharmafocus is published by:Samedan Ltd
Suite E, 11 Bell Yard Mews,
175 Bermondsey Street,
London, SE1 3TN
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747
www.pharmafile.comSubscriptions & Data ManagementCurwood CMS Tel: 01580 883840enquiries@c-cms.comISSN: 1465-5403
Pharmafocus is sent free of charge to selected permanent employees of ethical and OTC pharmaceutical and biotech companies. Employees are specifiers from middle and senior management with responsibility for making buying decisions. Selection is at the discretion of the Publisher. Copies are also available on a subscription basis at an annual fee of £115 (UK), £145 (Europe) and £185 (RoW).All subscriptions payable to Samedan. Back copies can be purchased for £15.00 each. Pharmafocus is published by Samedan Ltd. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form without permission, unless for the purposes of reference and comment.©2022 Samedan Ltd, Pharmaceutical PublishersThe opinions and views expressed by contributors to this publication are not necessarily those of the Editor or the Publisher and, while every care has been taken in the preparation of the newspaper, the Editor and the Publisher are not responsible for such opinions and views, or for any inaccuracies in the articles. The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means – electronic, mechanical, photocopying or otherwise – without the prior permission of the Publisher.